Abstract
Background: Terpene lactones are major components of ginkgo biloba extract which are used in cardiovascular and degenerative diseases. To study the involvement of transporters in the transport/disposition of ginkgolides A, B, C, and bilobalide, a bioanalytical assay was developed by LCMS/ MS system for the quantitation of intracellular levels of terpene lactones in cells expressing organic cation transporter 2 (OCT2).
Methods: The assay involved an optimized simple sample handling with methyl tert-butyl ether for liquid-liquid extraction and reconstitution in modified dissolution solution. Pretreatment of samples with 50 μM ascorbic acid and the addition of ascorbic acid and formic acid in dissolution solution significantly reduced matrix effect and stabilized the postpreparative samples. Separations were performed by Zobrax RRHD column (extend-C18 1.8μm, 3.0 x 100mm) and acetonitrile gradient elution. The analysis was carried out in the negative ion scan mode using multiple reaction monitoring.
Results: The method was validated for linearity (concentration range of 20-5000nM), accuracy (±13.1%), precision (<11.0%), recovery (94.31–105.9%), matrix effect (93.8-111.0%) and stability. Finally, the method was applied in the determination of intracellular concentrations of ginkgolides A, B, C, and bilobalide in Madin-Darby canine kidney (MDCK-mock) and MDCK-OCT2 cells in uptake study.
Conclusion: The developed method was successfully validated. Results suggest that OCT2 is involved in the renal disposition of ginkgolide A, B, and bilobalide. This method would foster the study of transport mediated activity via the interaction of ginkgolides and bilobalide with cellular systems.
Keywords: Ginkgolides, bilobalide, LC-MS/MS, matrix effect, uptake transport, MDCK-OCT2.
Graphical Abstract
[1]
Herring, T. Rapid determination of terpene lactones in Ginkgo Biloba commercial products by HPLC with evaporative light-scattering detection. LC GC N. Am., 2004, 22(5), 456-462.
[2]
Biber, A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry, 2003, 36(Suppl. 1), S32-S37.
[http://dx.doi.org/10.1055/s-2003-40446] [PMID: 13130386]
[http://dx.doi.org/10.1055/s-2003-40446] [PMID: 13130386]
[3]
Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia (2015 version); China Medical Science Press: Beijing, 2015.
[4]
Kudolo, G.B.; Dorsey, S.; Blodgett, J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb. Res., 2002, 108(2-3), 151-160.
[http://dx.doi.org/10.1016/S0049-3848(02)00394-8] [PMID: 12590952]
[http://dx.doi.org/10.1016/S0049-3848(02)00394-8] [PMID: 12590952]
[5]
Oken, B.S.; Storzbach, D.M.; Kaye, J.A. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol., 1998, 55(11), 1409-1415.
[http://dx.doi.org/10.1001/archneur.55.11.1409] [PMID: 9823823]
[http://dx.doi.org/10.1001/archneur.55.11.1409] [PMID: 9823823]
[6]
van Dongen, M.; van Rossum, E.; Kessels, A.; Sielhorst, H.; Knipschild, P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J. Clin. Epidemiol., 2003, 56(4), 367-376.
[http://dx.doi.org/10.1016/S0895-4356(03)00003-9] [PMID: 12767414]
[http://dx.doi.org/10.1016/S0895-4356(03)00003-9] [PMID: 12767414]
[7]
Grollino, M.G.; Raschellà, G.; Cordelli, E.; Villani, P.; Pieraccioli, M.; Paximadas, I.; Malandrino, S.; Bonassi, S.; Pacchierotti, F. Cytotoxicity, genotoxicity and gene expression changes elicited by exposure of human hepatic cells to Ginkgo biloba leaf extract. Food Chem. Toxicol., 2017, 109(Pt 1), 486-496.
[http://dx.doi.org/10.1016/j.fct.2017.09.042] [PMID: 28943387]
[http://dx.doi.org/10.1016/j.fct.2017.09.042] [PMID: 28943387]
[8]
DeFeudis, F.V.; Papadopoulos, V.; Drieu, K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam. Clin. Pharmacol., 2003, 17(4), 405-417.
[http://dx.doi.org/10.1046/j.1472-8206.2003.00156.x] [PMID: 12914542]
[http://dx.doi.org/10.1046/j.1472-8206.2003.00156.x] [PMID: 12914542]
[9]
Woelkart, K.; Feizlmayr, E.; Dittrich, P.; Beubler, E.; Pinl, F.; Suter, A.; Bauer, R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother. Res., 2010, 24(3), 445-450.
[http://dx.doi.org/10.1002/ptr.3074] [PMID: 20041430]
[http://dx.doi.org/10.1002/ptr.3074] [PMID: 20041430]
[10]
Choi, Y.H.; Chin, Y.W.; Kim, Y.G. Herb-drug interactions: focus on metabolic enzymes and transporters. Arch. Pharm. Res., 2011, 34(11), 1843-1863.
[http://dx.doi.org/10.1007/s12272-011-1106-z] [PMID: 22139685]
[http://dx.doi.org/10.1007/s12272-011-1106-z] [PMID: 22139685]
[11]
Fourtillan, J.B.; Brisson, A.M.; Girault, J.; Ingrand, I.; Decourt, J.P.; Drieu, K.; Jouenne, P.; Biber, A. [Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761)]. Therapie, 1995, 50(2), 137-144.
[PMID: 7631288]
[PMID: 7631288]
[12]
Ramawat, K.G.; Dass, S.; Mathur, M. Herbal drugs: ethnomedicine to modern medicine; Springer, 2009.
[http://dx.doi.org/10.1007/978-3-540-79116-4]
[http://dx.doi.org/10.1007/978-3-540-79116-4]
[13]
Qiu, Z.; Wang, L.; Dai, Y.; Ren, W.; Jiang, W.; Chen, X.; Li, N. The potential drug-drug interactions of ginkgolide B mediated by renal transporters. Phytother. Res., 2015, 29(5), 662-667.
[http://dx.doi.org/10.1002/ptr.5294] [PMID: 25589475]
[http://dx.doi.org/10.1002/ptr.5294] [PMID: 25589475]
[14]
Lv, H.; Wang, G.; Wu, X.; Xie, L.; Huang, C.; Li, H.; Liang, Y.; Hao, H.; Sun, J. Transport characteristics of ginkgolide B by CaCO2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method. Int. J. Pharm., 2008, 351(1-2), 31-35.
[http://dx.doi.org/10.1016/j.ijpharm.2007.09.026] [PMID: 17983711]
[http://dx.doi.org/10.1016/j.ijpharm.2007.09.026] [PMID: 17983711]
[15]
Wang, L.; Halquist, M.S.; Sweet, D.H. Simultaneous determination of gallic acid and gentisic acid in organic anion transporter expressing cells by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2013, 937, 91-96.
[http://dx.doi.org/10.1016/j.jchromb.2013.08.024] [PMID: 24022056]
[http://dx.doi.org/10.1016/j.jchromb.2013.08.024] [PMID: 24022056]
[16]
U.S. Food and Drug Administration. Clinical Drug Interaction Studies - Study Design; Data Analysis, and Clinical Implications Guidance for Industry, 2017.
[17]
Daumar, P.; Dufour, R.; Dubois, C.; Penault-Llorca, F.; Bamdad, M.; Mounetou, E. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. J. Pharm. Biomed. Anal., 2018, 152, 74-80.
[http://dx.doi.org/10.1016/j.jpba.2018.01.036] [PMID: 29414021]
[http://dx.doi.org/10.1016/j.jpba.2018.01.036] [PMID: 29414021]
[18]
Qiu, J.Y.; Chen, X.; Li, Z.; Wang, S.R.; Wu, X.W.; Li, Y.J.; Yang, D.Z.; Yu, Y.Y.; Yin, X.X.; Tang, D.Q. LC-MS/MS method for the simultaneous quantification of 11 compounds of Ginkgo biloba extract in lysates of mesangial cell cultured by high glucose. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2015, 997, 122-128.
[http://dx.doi.org/10.1016/j.jchromb.2015.06.002] [PMID: 26113453]
[http://dx.doi.org/10.1016/j.jchromb.2015.06.002] [PMID: 26113453]
[19]
U.S. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation., 2013.
[20]
Qin, Z.; Zhao, L.; Hu, H.; Jiang, H.; Yu, L.; Zeng, S. Utilizing single- and double-transfected cell models expressing human organic anion transporter 1 and human cytochrome P450 1A2 to investigate the interactions with ingredients of herbal medicines. Xenobiotica, 2017, 47(7), 576-583.
[http://dx.doi.org/10.1080/00498254.2016.1211774] [PMID: 27485257]
[http://dx.doi.org/10.1080/00498254.2016.1211774] [PMID: 27485257]
[21]
Yan, Z.; Caldwell, G. Optimization in drug discovery: in vitro methods; Springer Science & Business Media, 2004.
[http://dx.doi.org/10.1385/1592598005]
[http://dx.doi.org/10.1385/1592598005]
[22]
Li, L.; Sun, S.; Weng, Y.; Song, F.; Zhou, S.; Bai, M.; Zhou, H.; Zeng, S.; Jiang, H. Interaction of six protoberberine alkaloids with human organic cation transporters 1, 2 and 3. Xenobiotica, 2016, 46(2), 175-183.
[http://dx.doi.org/10.3109/00498254.2015.1056283] [PMID: 26134304]
[http://dx.doi.org/10.3109/00498254.2015.1056283] [PMID: 26134304]
[23]
Xie, J.; Ding, C.; Ge, Q.; Zhou, Z.; Zhi, X. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 864(1-2), 87-94.
[http://dx.doi.org/10.1016/j.jchromb.2008.01.045] [PMID: 18295555]
[http://dx.doi.org/10.1016/j.jchromb.2008.01.045] [PMID: 18295555]
[24]
Li, J.; Li, D.; Hu, J.; Bi, Y.; Xiao, W.; Wang, Z. Simultaneous determination of ginkgolides A, B, C and bilobalide by LC-MS/MS and its application to a pharmacokinetic study in rats. Biomed. Chromatogr., 2015, 29(12), 1907-1912.
[http://dx.doi.org/10.1002/bmc.3515] [PMID: 26010697]
[http://dx.doi.org/10.1002/bmc.3515] [PMID: 26010697]
[25]
Ni, M.W.; Zhou, J.; Li, H.; Chen, W.; Mou, H.Z.; Zheng, Z.G. Simultaneous determination of six tyrosine kinase inhibitors in human plasma using HPLC-Q-Orbitrap mass spectrometry. Bioanalysis, 2017, 9(12), 925-935.
[http://dx.doi.org/10.4155/bio-2017-0031] [PMID: 28617069]
[http://dx.doi.org/10.4155/bio-2017-0031] [PMID: 28617069]
[26]
Li, H.; Jiang, Z.; Cao, X.; Su, H.; Shao, H.; Jin, F.; Abd El-Aty, A.M.; Wang, J. Simultaneous determination of three pesticide adjuvant residues in plant-derived agro-products using liquid chromatography-tandem mass spectrometry. J. Chromatogr. A, 2017, 1528, 53-60.
[http://dx.doi.org/10.1016/j.chroma.2017.10.075] [PMID: 29103596]
[http://dx.doi.org/10.1016/j.chroma.2017.10.075] [PMID: 29103596]
[27]
Ma, S.; Liu, X.; Xu, Q.; Zhang, X. Transport of ginkgolides with different lipophilicities based on an hCMEC/D3 cell monolayer as a blood-brain barrier cell model. Life Sci., 2014, 114(2), 93-101.
[http://dx.doi.org/10.1016/j.lfs.2014.08.006] [PMID: 25139831]
[http://dx.doi.org/10.1016/j.lfs.2014.08.006] [PMID: 25139831]
[28]
Harper, J.N.; Wright, S.H. Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2. Am. J. Physiol. Renal Physiol., 2013, 304(1), F56-F67.
[http://dx.doi.org/10.1152/ajprenal.00486.2012] [PMID: 23034939]
[http://dx.doi.org/10.1152/ajprenal.00486.2012] [PMID: 23034939]
[29]
Belzer, M.; Morales, M.; Jagadish, B.; Mash, E.A.; Wright, S.H. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. J. Pharmacol. Exp. Ther., 2013, 346(2), 300-310.
[http://dx.doi.org/10.1124/jpet.113.203257] [PMID: 23709117]
[http://dx.doi.org/10.1124/jpet.113.203257] [PMID: 23709117]
[30]
Hacker, K.; Maas, R.; Kornhuber, J.; Fromm, M.F.; Zolk, O. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. PLoS One, 2015, 10(9)e0136451
[http://dx.doi.org/10.1371/journal.pone.0136451] [PMID: 26327616]
[http://dx.doi.org/10.1371/journal.pone.0136451] [PMID: 26327616]
[31]
Liu, X.W.; Yang, J.L.; Niu, W.; Jia, W.W.; Olaleye, O.E.; Wen, Q.; Duan, X.N.; Huang, Y.H.; Wang, F.Q.; Du, F.F.; Zhong, C.C.; Li, Y.F.; Xu, F.; Gao, Q.; Li, L.; Li, C. Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity. Acta Pharmacol. Sin., 2018, 39(12), 1935-1946.
[http://dx.doi.org/10.1038/s41401-018-0086-7] [PMID: 30054600]
[http://dx.doi.org/10.1038/s41401-018-0086-7] [PMID: 30054600]
Article Metrics
22
1